Plexiform angiomyxoid myofibroblastic tumor

Last updated

Plexiform angiomyxoid myofibroblastic tumor (PAMT), also called plexiform angiomyxoma, [1] plexiform angiomyxoid tumor, [2] or myxofibroma, [3] is an extremely rare benign mesenchymal myxoid tumor along the gastrointestinal tract. Most of PAMTs occur in the gastric antral region, but they can be situated anywhere in the stomach. There is one recorded case of PAMT located in duodenum. [4]

Contents

Classification

PAMT was first described by Takahashi et al. in 2007. [5] Estimated frequency of PAMT is less than 1/150 compared to that of gastrointestinal stromal tumors (GISTs). [1] The prevalence is similar in both genders and can develop at any age (7–75 years). [4] The size of tumor ranges from 1.9 to 15.0 cm and the mean value is 6.3 cm.

PAMT is considered as a benign tumor, due to its histological features such as the presence of bland tumor cells, low proliferation index, low mitotic-rate, absence of necrosis and vascular invasion and no recurrence. [5] In one case there has been reported vascular invasion, thus possibility of malignant transformation cannot be excluded. But the limited number of reported cases is insufficient to draw any conclusion. [6] The true biological potential of PAMT remains unknown due to its infrequency.

Presentation

Most patients present certain symptoms including anaemia due to hematemesis, ulceration, gastric outlet obstruction, fistulating abscess formation, intermittent epigastric discomfort and abdominal pain, nausea, vomiting, weight loss, or could be asymptomatic with incidental finding. [2] [5]

Diagnosis

Accurate diagnosis of early PAMT is difficult, but there are certain morphological and immunophenotypic features enabling differentiation of this tumor from GIST or other mesenchymal gastric tumors. The diagnosis of submucosal tumors is performed by endoscopic ultrasonography (EUS), whereas the tumor phenotype and the tumor cell type can be evaluated by EUS-guided fine needle aspiration and immunohistochemical analysis. [7]

Immunohistochemically, the tumour cells show positive staining for vimentin and smooth muscle actin (SMA). Focal desmin positivity may be present. The tumour cells are generally negative for CD117, DOG1, SMA, Caldesmon, CD34, Epithelial membrane antigen (EMA), Cytokeratin or Anaplastic lymphoma kinase (ALK). Focal CD10 positivity can be observed. The pattern of positivity indicates the myofibroblastic nature of the tumour cells. [8]

Pathological features

Macroscopically, the tumour manifests as elevated or polypoidal mass lesion most commonly affecting the antral region of the stomach, however, in some cases fundus [9] and body of the stomach as well as esophagus [10] might be involved. Duodenal bulb or the pylorus are involved roughly in 33% cases. [5]

Microscopically, the gastric wall shows a characteristic multinodular plexiform pattern of the tumour. The uppermost layer of mucosa is in many cases ulcerated. The fascicular arrangement of the tumour can be observed focally. The tumour cells are entrenched in a highly vasculated myxoid background.

The vessels are thin arborizing with or without thrombi. The individual tumour cells are spindle to ovoid shaped, with indistinct cell borders, bland nuclear chromatin, inconspicuous nucleoli, and scant eosinophilic cytoplasm. Mitotic rate is low. Stromal collagenisation is inconspicuous. The myxoid background stroma stain positive for Alcian blue stain. Many mast cells can be seen dispersed in the stroma. [8]

Treatment

Currently, the treatment of choice for PAMTs is distal or partial gastrectomy. [11] Further studies could provide more information about its histogenesis and molecular signature that could be applied in targeted therapeutic approach.

Prognosis

PAMT has a seemingly good prognosis without reported relapse or metastasis. Due to tumors small size and a good prognosis it is possible to remove this tumor by endoscopic submucosal dissection (ESD) under gastroscopy at an early stage. [12]

Related Research Articles

<span class="mw-page-title-main">Stomach cancer</span> Cancerous tumor originating in the stomach lining

Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach. Most cases of stomach cancers are gastric carcinomas, which can be divided into a number of subtypes, including gastric adenocarcinomas. Lymphomas and mesenchymal tumors may also develop in the stomach. Early symptoms may include heartburn, upper abdominal pain, nausea, and loss of appetite. Later signs and symptoms may include weight loss, yellowing of the skin and whites of the eyes, vomiting, difficulty swallowing, and blood in the stool, among others. The cancer may spread from the stomach to other parts of the body, particularly the liver, lungs, bones, lining of the abdomen, and lymph nodes.

<span class="mw-page-title-main">Gastrointestinal stromal tumor</span> Human disease (cancer)

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. GISTs arise in the smooth muscle pacemaker interstitial cell of Cajal, or similar cells. They are defined as tumors whose behavior is driven by mutations in the KIT gene (85%), PDGFRA gene (10%), or BRAF kinase (rare). 95% of GISTs stain positively for KIT (CD117). Most (66%) occur in the stomach and gastric GISTs have a lower malignant potential than tumors found elsewhere in the GI tract.

<span class="mw-page-title-main">Gastrin</span> Mammalian protein found in Homo sapiens

Gastrin is a peptide hormone that stimulates secretion of gastric acid (HCl) by the parietal cells of the stomach and aids in gastric motility. It is released by G cells in the pyloric antrum of the stomach, duodenum, and the pancreas.

<span class="mw-page-title-main">Gastric varices</span> Medical condition

Gastric varices are dilated submucosal veins in the lining of the stomach, which can be a life-threatening cause of bleeding in the upper gastrointestinal tract. They are most commonly found in patients with portal hypertension, or elevated pressure in the portal vein system, which may be a complication of cirrhosis. Gastric varices may also be found in patients with thrombosis of the splenic vein, into which the short gastric veins that drain the fundus of the stomach flow. The latter may be a complication of acute pancreatitis, pancreatic cancer, or other abdominal tumours, as well as hepatitis C. Gastric varices and associated bleeding are a potential complication of schistosomiasis resulting from portal hypertension.

<span class="mw-page-title-main">Sex cord–gonadal stromal tumour</span> Medical condition

Sex cord–gonadal stromal tumour is a group of tumours derived from the stromal component of the ovary and testis, which comprises the granulosa, thecal cells and fibrocytes. In contrast, the epithelial cells originate from the outer epithelial lining surrounding the gonad while the germ cell tumors arise from the precursor cells of the gametes, hence the name germ cell. In humans, this group accounts for 8% of ovarian cancers and under 5% of testicular cancers. Their diagnosis is histological: only a biopsy of the tumour can make an exact diagnosis. They are often suspected of being malignant prior to operation, being solid ovarian tumours that tend to occur most commonly in post menopausal women.

<span class="mw-page-title-main">Dermatofibrosarcoma protuberans</span> Medical condition

Dermatofibrosarcoma protuberans (DFSP) is a rare locally aggressive malignant cutaneous soft-tissue sarcoma. DFSP develops in the connective tissue cells in the middle layer of the skin (dermis). Estimates of the overall occurrence of DFSP in the United States are 0.8 to 4.5 cases per million persons per year. In the United States, DFSP accounts for between 1 and 6 percent of all soft-tissue sarcomas and 18 percent of all cutaneous soft-tissue sarcomas. In the Surveillance, Epidemiology and End Results (SEER) tumor registry from 1992 through 2004, DFSP was second only to Kaposi sarcoma.

<span class="mw-page-title-main">Hamartoma</span> Tumour-like overgrowth due to a systemic genetic condition

A hamartoma is a mostly benign, local malformation of cells that resembles a neoplasm of local tissue but is usually due to an overgrowth of multiple aberrant cells, with a basis in a systemic genetic condition, rather than a growth descended from a single mutated cell (monoclonality), as would typically define a benign neoplasm/tumor. Despite this, many hamartomas are found to have clonal chromosomal aberrations that are acquired through somatic mutations, and on this basis the term hamartoma is sometimes considered synonymous with neoplasm. Hamartomas are by definition benign, slow-growing or self-limiting, though the underlying condition may still predispose the individual towards malignancies.

<span class="mw-page-title-main">Gastrinoma</span> Medical condition

Gastrinomas are neuroendocrine tumors (NETs), usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger–Ellison syndrome (ZES). A large number of gastrinomas develop in the pancreas or duodenum, with near-equal frequency, and approximately 10% arise as primary neoplasms in lymph nodes of the pancreaticoduodenal region.

<span class="mw-page-title-main">Interstitial cell of Cajal</span>

Interstitial cells of Cajal (ICC) are interstitial cells found in the gastrointestinal tract. There are different types of ICC with different functions. ICC and another type of interstitial cell, known as platelet-derived growth factor receptor alpha (PDGFRα) cells, are electrically coupled to smooth muscle cells via gap junctions, that work together as an SIP functional syncytium. Myenteric interstitial cells of Cajal (ICC-MY) serve as pacemaker cells that generate the bioelectrical events known as slow waves. Slow waves conduct to smooth muscle cells and cause phasic contractions.

<span class="mw-page-title-main">Gastric antral vascular ectasia</span> Medical condition of the stomach

Gastric antral vascular ectasia (GAVE) is an uncommon cause of chronic gastrointestinal bleeding or iron deficiency anemia. The condition is associated with dilated small blood vessels in the pyloric antrum, which is a distal part of the stomach. The dilated vessels result in intestinal bleeding. It is also called watermelon stomach because streaky long red areas that are present in the stomach may resemble the markings on watermelon.

<span class="mw-page-title-main">Gastric lymphoma</span> Medical condition

Primary gastric lymphoma is an uncommon condition, accounting for less than 15% of gastric malignancies and about 2% of all lymphomas. However, the stomach is a very common extranodal site for lymphomas. It is also the most common source of lymphomas in the gastrointestinal tract.

<span class="mw-page-title-main">Signet ring cell carcinoma</span> Medical condition

Signet ring cell carcinoma (SRCC) is a rare form of highly malignant adenocarcinoma that produces mucin. It is an epithelial malignancy characterized by the histologic appearance of signet ring cells.

Fibrous hamartoma of infancy (FHI) is a rare, typically painless, benign tumor that develops in the subcutaneous tissues of the axilla, arms, external genitalia, or, less commonly, various other areas. It is diagnosed in children who are usually less than 2 years old or, in up to 20% of cases, develops in utero and is diagnosed in an infant at birth.

<span class="mw-page-title-main">Low-grade fibromyxoid sarcoma</span> Medical condition

Low-grade fibromyxoid sarcoma (LGFMS) is a rare type of low-grade sarcoma first described by H. L. Evans in 1987. LGFMS are soft tissue tumors of the mesenchyme-derived connective tissues; on microscopic examination, they are found to be composed of spindle-shaped cells that resemble fibroblasts. These fibroblastic, spindle-shaped cells are neoplastic cells that in most cases of LGFMS express fusion genes, i.e. genes composed of parts of two different genes that form as a result of mutations. The World Health Organization (2020) classified LGFMS as a specific type of tumor in the category of malignant fibroblastic and myofibroblastic tumors.

<span class="mw-page-title-main">Inflammatory fibroid polyp</span> Medical condition

An inflammatory fibroid polyp(IFP) is an uncommon digestive system tumor. J. Vanek initially identified it as a separate pathological entity in 1949 when he reported six case reports of eosinophilic infiltration in gastric submucosal granulomas. It is a single, non-encapsulated polypoid lesion that is typically submucosal. It is characterized by a large number of small blood vessels, oedematous connective tissue, and an inflammatory eosinophilic infiltrate.

Ectomesenchymal chondromyxoid tumor (ECT) is a benign intraoral tumor with presumed origin from undifferentiated (ecto)mesenchymal cells. There are some who think it is a myoepithelial tumor type.

Hilda Tracy worked at University of Liverpool, UK, with Rod Gregory FRS to isolate and characterise the gastrointestinal hormone gastrin. She led the structure-function studies and had the first insight into gastrin's role in the clinical pathology of pancreatic Zollinger-Ellison tumours.

Gastroblastoma is a rare cancer that occurs in the stomach. Only six cases have been reported to date (2017).

Acral myxoinflammatory fibroblastic sarcoma (AMSF), also termed myxoinflammatory fibroblastic sarcoma (MSF), is a rare, low-grade, soft tissue tumor that the World Health Organization (2020) classified as in the category of rarely metastasizing fibroblastic and myofibroblastic tumors. It is a locally aggressive neoplasm that often recurs at the site of its surgical removal. However, it usually grows slowly and in only 1–2% of cases spreads to distant tissues.

Fibroblastic and myofibroblastic tumors (FMTs) develop from the mesenchymal stem cells which differentiate into fibroblasts and/or the myocytes/myoblasts that differentiate into muscle cells. FMTs are a heterogeneous group of soft tissue neoplasms. The World Health Organization (2020) defined tumors as being FMTs based on their morphology and, more importantly, newly discovered abnormalities in the expression levels of key gene products made by these tumors' neoplastic cells. Histopathologically, FMTs consist of neoplastic connective tissue cells which have differented into cells that have microscopic appearances resembling fibroblasts and/or myofibroblasts. The fibroblastic cells are characterized as spindle-shaped cells with inconspicuous nucleoli that express vimentin, an intracellular protein typically found in mesenchymal cells, and CD34, a cell surface membrane glycoprotein. Myofibroblastic cells are plumper with more abundant cytoplasm and more prominent nucleoli; they express smooth muscle marker proteins such as smooth muscle actins, desmin, and caldesmon. The World Health Organization further classified FMTs into four tumor forms based on their varying levels of aggressiveness: benign, intermediate, intermediate, and malignant.

References

  1. 1 2 Yoshida, Akihiko; Klimstra, David S.; Antonescu, Cristina R. (December 2008). "Plexiform Angiomyxoid Tumor of the Stomach". The American Journal of Surgical Pathology. 32 (12): 1910–1912. doi:10.1097/pas.0b013e3181838fd1. ISSN   0147-5185. PMID   18824895.
  2. 1 2 Miettinen, Markku; Makhlouf, Hala R.; Sobin, Leslie H.; Lasota, Jerzy (November 2009). "Plexiform Fibromyxoma". The American Journal of Surgical Pathology. 33 (11): 1624–1632. doi:10.1097/pas.0b013e3181ae666a. ISSN   0147-5185. PMID   19675452. S2CID   24634903.
  3. ↑ Ikemura, Masako; Maeda, Eriko; Hatao, Fumihiko; Aikou, Susumu; Seto, Yasuyuki; Fukayama, Masashi (2014-01-15). "Plexiform angiomyxoid myofibroblastic tumor (PAMT) of the stomach. A case report focusing on its characteristic growth pattern". International Journal of Clinical and Experimental Pathology. 7 (2): 685–689. ISSN   1936-2625. PMC   3925914 . PMID   24551290.
  4. 1 2 Banerjee, Niladri; Gupta, Shahana; Dash, Suvashis; Ghosh, Shibajyoti (2015-07-27). "Plexiform angiomyxoid myofibroblastic tumour of the duodenum: a rare entity". BMJ Case Reports. 2015: bcr2015210004. doi:10.1136/bcr-2015-210004. ISSN   1757-790X. PMC   4521542 . PMID   26216925.
  5. 1 2 3 4 Takahashi, Yoshihisa; Suzuki, Masako; Fukusato, Toshio (2010-06-21). "Plexiform angiomyxoid myofibroblastic tumor of the stomach". World Journal of Gastroenterology. 16 (23): 2835–2840. doi: 10.3748/wjg.v16.i23.2835 . ISSN   1007-9327. PMC   2887578 . PMID   20556828.
  6. ↑ Rau, T. T.; Hartmann, A.; Dietmaier, W.; Schmitz, J.; Hohenberger, W.; Hofstaedter, F.; Katenkamp, K. (2008-10-01). "Plexiform angiomyxoid myofibroblastic tumour: differential diagnosis of gastrointestinal stromal tumour in the stomach". Journal of Clinical Pathology. 61 (10): 1136–1137. doi:10.1136/jcp.2008.059162. ISSN   0021-9746. PMID   18820104. S2CID   25531956.
  7. ↑ Schulz, T.; Drgac, J.; Chmelar, C.; Höhler, T.; Agaimy, A.; Vieth, M. (2012-01-29). "Plexiformer angiomyxoider myofibroblastischer Tumor des Magens". Der Pathologe (in German). 33 (1): 65–69. doi:10.1007/s00292-011-1548-6. ISSN   0172-8113. PMID   22293792. S2CID   28172337.
  8. 1 2 Li, Peifeng; Yang, Shaolong; Wang, Cuicui; Li, Yamin; Geng, Ming (2014-01-15). "Presence of smooth muscle cell differentiation in plexiform angiomyxoid myofibroblastic tumor of the stomach: a case report". International Journal of Clinical and Experimental Pathology. 7 (2): 823–827. ISSN   1936-2625. PMC   3925935 . PMID   24551311.
  9. ↑ Wang, Wei-ya; Li, Jin-nan; Li, Gan-di (2010-06-01). "Plexiform angiomyxoid myofibroblastic tumour of the gastric fundus: successful diagnosis and treatment by endoscopy". Journal of Clinical Pathology. 63 (6): 569–570. doi:10.1136/jcp.2010.076646. ISSN   0021-9746. PMID   20498030. S2CID   6901612.
  10. ↑ Duckworth, Lizette Vila; Gonzalez, Raul S.; Martelli, Matthew; Liu, Chen; Coffin, Cheryl M.; Reith, John D. (January 2014). "Plexiform Fibromyxoma: Report of Two Pediatric Cases and Review of the Literature". Pediatric and Developmental Pathology. 17 (1): 21–27. doi:10.2350/13-09-1373-oa.1. ISSN   1093-5266. PMID   24160555. S2CID   24010632.
  11. ↑ Dekate, Jyoti; Ali-Ridha, Nihad; Vajpeyi, Rajkumar (June 2015). "Gastric plexiform angiomyxoid myofibroblastic tumour". Diagnostic Histopathology. 21 (6): 257–260. doi:10.1016/j.mpdhp.2015.06.013. ISSN   1756-2317.
  12. ↑ Li, Xi; Li, Shuangqing; Xiong, Shenghua; Wang, Zhujun; Zhang, Hu (2016). "A rare case of plexiform angiomyxoid myofibroblastic tumor in the stomach which was diagnosed at the earliest stage in the literature". Gastroenterology Report. 6 (4): 313–316. doi:10.1093/gastro/gow035. PMC   6225817 . PMID   27940603.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.